



— SampleName: 2.35 #13 sir n; Vial: 1.C.2; Injection: 1; Channel Description 1: QDa Positive(+) SIR Ch1 178.00 Da, CV=15; Channel: QDa 1: SIR Ch1; Date Acquired: 3/4/2020 1:46:52 PM CET
— SampleName: 2.35 #13 sir n; Vial: 1.C.2; Injection: 1; Channel Description 2: QDa Negative(-) SIR Ch9 436.00 Da, CV=15; Channel: QDa 2: SIR Ch7; Date Acquired: 3/4/2020 1:46:52 PM CET
— SampleName: 2.35 #13 sir n; Vial: 1.C.2; Injection: 1; Channel Description 2: QDa Negative(-) SIR Ch7 422.00 Da, CV=15; Channel: QDa 2: SIR Ch5; Date Acquired: 3/4/2020 1:46:52 PM CET
— SampleName: 2.35 #13 sir n; Vial: 1.C.2; Injection: 1; Channel Description 2: QDa Negative(-) SIR Ch6 420.00 Da, CV=15; Channel: QDa 2: SIR Ch4; Date Acquired: 3/4/2020 1:46:52 PM CET
— SampleName: 2.35 #13 sir n; Vial: 1.C.2; Injection: 1; Channel Description 2: QDa Negative(-) SIR Ch11 463.00 Da, CV=15; Channel: QDa 2: SIR Ch9; Date Acquired: 3/4/2020 1:46:52 PM CET
— SampleName: 2.35 #13 sir n; Vial: 1.C.2; Injection: 1; Channel Description 2: QDa Negative(-) SIR Ch10 447.00 Da, CV=15; Channel: QDa 2: SIR Ch8; Date Acquired: 3/4/2020 1:46:52 PM CET
— SampleName: 2.35 #13 sir n; Vial: 1.C.2; Injection: 1; Channel Description 2: QDa Negative(-) SIR Ch12 477.00 Da, CV=15; Channel: QDa 2: SIR Ch10; Date Acquired: 3/4/2020 1:46:52 PM CET